Clinical Trial Update: A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating adverse events and changes in disease activity in adults with moderately to severely active Crohn's disease treated with ABBV-154 via I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• ABBV-154

Snippet

Sponsor: AbbVie | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED | Results posted: 2024-10-03